Accelerating Vaccine Development and Manufacturing
The use of approved platform technologies can reduce the time and cost required to generate new vaccines.
Established vaccine manufacturing technologies are complex, often highly customized, and typically require dedicated facilities. Development and approval times can be lengthy, presenting hurdles for medical professionals seeking rapid response to pandemic diseases.
Standardized vaccine manufacturing platforms that can be deployed across different vaccines and vaccine types, could speed the delivery of vaccines and enable manufacturing in emerging economies. Technical and funding challenges must be overcome to bring the advanced manufacturing potential to reality.
Download
Pharmaceutical Technology and BioPharm International’s 2017 Vaccine Development and Manufacturing 2017eBook.
Article Details
Pharmaceutical Technology and BioPharm International
eBook: Vaccine Development and Manufacturing 2017
November 2017
Pages: 11–19
Citation
When referring to this article, please cite it as C Challener, " Accelerating Vaccine Development and Manufacturing," Pharmaceutical Technology and BioPharm International Vaccine Development and Manufacturing 2017 eBook (November 2017).
Thermo Fisher Opens Advanced Therapies Collaboration Center in California
April 18th 2025The 6000-square-foot facility will provide cell therapy developers the support they need to transition to CGMP manufacturing, and an expanded footprint of the new center is expected to open in Philadelphia later in 2025.
